High-Plex Spatially Resolved RNA and Protein Detection Using Digital Spatial Profiling: A Technology Designed for Immuno-oncology Biomarker Discovery and Translational Research
- PMID: 31502169
- DOI: 10.1007/978-1-4939-9773-2_25
High-Plex Spatially Resolved RNA and Protein Detection Using Digital Spatial Profiling: A Technology Designed for Immuno-oncology Biomarker Discovery and Translational Research
Abstract
Digital spatial profiling (DSP) is a nondestructive method for high-plex spatial profiling of proteins and RNA from a wide variety of sample types, including formalin-fixed, paraffin-embedded (FFPE) tissue sections. This method uses small photocleavable oligonucleotide "barcodes" (PC-oligos) covalently attached to in-situ affinity reagents (antibodies and RNA-probes) to provide unlimited multiplexing capability. The photocleavage light is projected onto the tissue slice using two-digital micromirror devices (DMD), containing one-million semiconductor-based micromirrors allowing complete flexibility in the pattern of light utilized for high-plex digital profiling of the tissue. These spatial light-patterns can be automatically configured to profile (1) "tumor-only" cells plus "tumor-microenvironment-only" cells; (2) unique cell types and rare cell features (e.g., macrophages, CD8, CD3, CD45, PD-L1 on macrophages, PD-L1 on tumors, etc.); (3) spatial gradients around cell-features or tumor features (e.g., excluded boundaries); (4) hypothesis-free spatial grids; (5) simple hand-selected geometric areas (e.g., free-hand software-based "drawing" on tissue regions); and (6) or any combination of the above modalities. These DMDs can automatically configure themselves to "align" to the biology presented by each individual tissue section. Advanced validated high-plex panels of proteins (~100-plex) and RNA (up to 20,000-plex) specifically designed for immuno-oncology (IO) have been developed. Immuno-oncology clinical trial samples examined using DSP have already provided key insights into the mechanism of action of combination therapy in melanoma, appearing recently in back-to-back articles published in Nature Medicine. DSP has been developed with knowledge of key immuno-oncology terms (tumor, tumor microenvironment, stroma, etc.) and prevalidated high-plex panels of affinity markers (antibodies and in situ RNA probes) and has the potential to bring the full power of high-plex molecular profiling to spatially resolved studies.
Keywords: Biomarkers; Digital spatial profiling; High-plex; Imaging; Immuno-oncology; Proteins; RNA.
Similar articles
-
Multiplex digital spatial profiling of proteins and RNA in fixed tissue.Nat Biotechnol. 2020 May;38(5):586-599. doi: 10.1038/s41587-020-0472-9. Epub 2020 May 11. Nat Biotechnol. 2020. PMID: 32393914
-
GeoMx™ RNA Assay: High Multiplex, Digital, Spatial Analysis of RNA in FFPE Tissue.Methods Mol Biol. 2020;2148:331-345. doi: 10.1007/978-1-0716-0623-0_21. Methods Mol Biol. 2020. PMID: 32394392
-
High-Plex Predictive Marker Discovery for Melanoma Immunotherapy-Treated Patients Using Digital Spatial Profiling.Clin Cancer Res. 2019 Sep 15;25(18):5503-5512. doi: 10.1158/1078-0432.CCR-19-0104. Epub 2019 Jun 12. Clin Cancer Res. 2019. PMID: 31189645 Free PMC article.
-
Spatial transcriptomics and proteomics technologies for deconvoluting the tumor microenvironment.Biotechnol J. 2021 Sep;16(9):e2100041. doi: 10.1002/biot.202100041. Epub 2021 Jun 27. Biotechnol J. 2021. PMID: 34125481 Review.
-
Challenges and Opportunities for Immunoprofiling Using a Spatial High-Plex Technology: The NanoString GeoMx® Digital Spatial Profiler.Front Oncol. 2022 Jun 29;12:890410. doi: 10.3389/fonc.2022.890410. eCollection 2022. Front Oncol. 2022. PMID: 35847846 Free PMC article. Review.
Cited by
-
Digital Spatial Profiling of Individual Glomeruli From Patients With Anti-Neutrophil Cytoplasmic Autoantibody-Associated Glomerulonephritis.Front Immunol. 2022 Mar 2;13:831253. doi: 10.3389/fimmu.2022.831253. eCollection 2022. Front Immunol. 2022. PMID: 35309370 Free PMC article.
-
Spatially Resolved, Multiregion Proteomics for Prediction of Immunotherapy Outcome in Deficient Mismatch Repair Metastatic Colorectal Cancer.Clin Cancer Res. 2025 May 1;31(9):1783-1795. doi: 10.1158/1078-0432.CCR-24-0853. Clin Cancer Res. 2025. PMID: 39969975
-
Clinical and biomarker results from a phase II trial of combined cabozantinib and durvalumab in patients with chemotherapy-refractory colorectal cancer (CRC): CAMILLA CRC cohort.Nat Commun. 2024 Feb 20;15(1):1533. doi: 10.1038/s41467-024-45960-2. Nat Commun. 2024. PMID: 38378868 Free PMC article. Clinical Trial.
-
Investigative needle core biopsies support multimodal deep-data generation in glioblastoma.Nat Commun. 2025 Apr 28;16(1):3957. doi: 10.1038/s41467-025-58452-8. Nat Commun. 2025. PMID: 40295505 Free PMC article.
-
Mapping Spatiotemporal Heterogeneity in Tumor Profiles by Integrating High-Throughput Imaging and Omics Analysis.ACS Omega. 2023 Feb 7;8(7):6126-6138. doi: 10.1021/acsomega.2c06659. eCollection 2023 Feb 21. ACS Omega. 2023. PMID: 36844580 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous